RJA
MEDP icon

Raymond James & Associates’s Medpace MEDP Stock Holding History

Raymond James & Associates’s Portfolio MEDP Stock Details MEDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$18.6M Buy
55,689
+954
+2% +$362K 0.01% 856
2024
Q2 		$22.5M Buy
54,735
+6,351
+13% +$2.52M 0.01% 715
2024
Q1 		$19.6M Buy
48,384
+1,375
+3% +$483K 0.01% 788
2023
Q4 		$14.4M Buy
47,009
+6,177
+15% +$1.67M 0.01% 896
2023
Q3 		$9.89M Sell
40,832
-11,871
-23% -$3.04M 0.01% 1041
2023
Q2 		$12.7M Sell
52,703
-879
-2% -$183K 0.01% 926
2023
Q1 		$10.1M Sell
53,582
-952
-2% -$197K 0.01% 1021
2022
Q4 		$11.6M Sell
54,534
-25,888
-32% -$5.17M 0.01% 914
2022
Q3 		$12.6M Buy
80,422
+8,562
+12% +$1.37M 0.01% 838
2022
Q2 		$10.8M Buy
71,860
+3,380
+5% +$489K 0.01% 945
2022
Q1 		$11.2M Buy
68,480
+27,710
+68% +$4.57M 0.01% 1003
2021
Q4 		$8.87M Buy
40,770
+1,200
+3% +$251K 0.01% 1172
2021
Q3 		$7.49M Buy
39,570
+726
+2% +$132K 0.01% 1236
2021
Q2 		$6.86M Buy
38,844
+754
+2% +$130K 0.01% 1287
2021
Q1 		$6.25M Sell
38,090
-2,558
-6% -$391K 0.01% 1293
2020
Q4 		$5.66M Buy
40,648
+2,615
+7% +$330K 0.01% 1271
2020
Q3 		$4.25M Sell
38,033
-1,678
-4% -$194K 0.01% 1314
2020
Q2 		$3.69M Buy
39,711
+22,566
+132% +$1.92M 0.01% 1373
2020
Q1 		$1.26M Buy
17,145
+4,933
+40% +$428K ﹤0.01% 1839
2019
Q4 		$1.03M Sell
12,212
-426
-3% -$33K ﹤0.01% 2251
2019
Q3 		$1.06M Sell
12,638
-422
-3% -$31.9K ﹤0.01% 2171
2019
Q2 		$854K Sell
13,060
-2,626
-17% -$151K ﹤0.01% 2312
2019
Q1 		$925K Sell
15,686
-6,098
-28% -$364K ﹤0.01% 2254
2018
Q4 		$1.15M Buy
21,784
+1,644
+8% +$90.2K ﹤0.01% 2002
2018
Q3 		$1.21M Buy
+20,140
New +$1.1M ﹤0.01% 2121
2018
Q1 		– Sell
-23,502
Closed -$852K – 3532
2017
Q4 		$852K Buy
23,502
+1,097
+5% +$38.5K ﹤0.01% 2219
2017
Q3 		$715K Sell
22,405
-53
-0.2% -$1.62K ﹤0.01% 2282
2017
Q2 		$651K Buy
+22,458
New +$630K ﹤0.01% 2267

Other funds holding MEDP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James & Associates's MEDP Position: Q3 2024 in Review

Raymond James & Associates increased its Medpace (MEDP) stake by 1.7% in Q3 2024, buying an estimated $362K and bringing the position to 55,689 shares worth $18.6M. The position accounts for 0.01% of the portfolio, ranked #856.

Raymond James & Associates first reported a position in MEDP in Q2 2017 and has held it in 28 quarters since. The position peaked at $22.5M in Q2 2024. 583 funds tracked by Wall St. Rank hold MEDP as of Q3 2024.

  • Raymond James & Associates held 55,689 shares of Medpace worth $18.6M as of Q3 2024.
  • Raymond James & Associates bought 954 Medpace shares in Q3 2024, an estimated $362K.
  • Medpace made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #856 holding.
  • Raymond James & Associates first reported a position in Medpace in Q2 2017 and has held it in 28 quarters since.
  • Raymond James & Associates's Medpace position peaked at $22.5M in Q2 2024.
  • 583 funds tracked by Wall St. Rank held Medpace as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.